Selskabets formål er salg og distribution af lægemidler, samt direkte eller indirekte at drive anden virksomhed, der efter bestyrelsens skøn er forbundet dermed.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 590.2 mio. | 6.8 mio. | 397.7 mio. | 20.6 mio. | 57 | |
CVR: 31501296
Secondary names: ALK-ABELLÓ DANMARK A/S
Compared to 406 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
The financial health of ALK-ABELLÓ NORDIC A/S appears to be improving, with a notable increase in revenue and profit over the past year. In 2024, the company reported revenue of 590.17 million DKK and a profit of 6.8 million DKK, up from 509.67 million DKK and 3.7 million DKK in 2023. This upward trend in profitability reflects a solid growth trajectory, particularly from 2022 to 2024, where profit surged from 908,000 DKK to 6.8 million DKK. The equity position has also strengthened, rising from 10.4 million DKK in 2022 to 20.6 million DKK in 2024, indicating a healthier balance sheet. However, the company operates in a competitive pharmaceutical wholesale market, and maintaining margins will be crucial for sustaining growth.
AI-generated summary
Companies in the same industry and area
CVR 28695780
CVR 16278394
CVR 15289732
CVR 26785464
CVR 28982968
companydata.dk